Page last updated: 2024-11-12

bn 52020

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9909368
CHEMBL ID465161
MeSH IDM0273540

Synonyms (31)

Synonym
AB00827840-06
bn52020
6h-9,4a-(epoxymethano)-3ah,9h-cyclopenta(c)furo(2,3-b)furo(3',2':3,4)cyclopenta(1,2-d)furan-2,6,13(1h)-trione, 11-(1,1-dimethylethyl)hexahydro-1,4b-dihydroxy-5-methyl-, (3ar,4ar,4br,5s,7as,8as,9r,11s, 11as)-
bn-52020
bn 52020
9h-1,7a-(epoxymethano)-1h,6ah-cyclopenta(c)furo(2,3-b)furo(3',2':3,4)cyclopenta(1,2-d)furan-5,9,12(4h)-trione, 3-(1,1-dimethylethyl)hexahydro-4,7b-dihydroxy-8-methyl-, (1r-(1alpha,3beta,3as*,4beta,6aalpha,7aalpha,7balpha,8alpha,10aalpha,11 as*))-
9h-1,7a-(epoxymethano)-1h,6ah-cyclopenta(c)furo(2,3-b)furo(3',2':3,4)cyclopenta(1,2-d)furan-5,9,12(4h)-trione, 3-tert-butylhexahydro-4,7b-dihydroxy-8-methyl-
smr000544404
MLS001216228
HMS2089P12
DB06743
ginkgolide-a
CHEMBL465161 ,
bdbm50292287
taz2dpr77b ,
unii-taz2dpr77b
9h-1,7a-(epoxymethano)-1h,6ah-cyclopenta(c)furo(2,3-b)furo(3',2':3,4)cyclopenta(1,2-d)furan-5,9,12(4h)-trione, 3-(1,1-dimethylethyl)hexahydro-4,7b-dihydroxy-8-methyl-, (1r,3s,3as,4r,6ar,7ar,7br,8s,10as,11as)-
HMS2864P03
ginkgolide a [mi]
ginkgolide a (constituent of ginkgo) [dsc]
ginkgolide a [who-dd]
Q-100178
AKOS030485969
SR-01000801389-2
sr-01000801389
DTXSID10873222 ,
Q27095718
119460-49-0
AS-17563
ginkgolide a (constituent of ginkgo)
dtxcid40820729

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency89.12510.010323.856763.0957AID2662
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glycine receptor subunit alpha-1Homo sapiens (human)IC50 (µMol)1.80320.02700.81873.8000AID281247; AID281248; AID281250
Glycine receptor subunit alpha-2Homo sapiens (human)IC50 (µMol)2.04761.99532.94413.9811AID281249
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)IC50 (µMol)3.80000.00040.15553.8000AID281250
Type-1B angiotensin II receptorRattus norvegicus (Norway rat)IC50 (µMol)3.80000.00040.13343.8000AID281250
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
startle responseGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processGlycine receptor subunit alpha-1Homo sapiens (human)
monoatomic ion transportGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transportGlycine receptor subunit alpha-1Homo sapiens (human)
muscle contractionGlycine receptor subunit alpha-1Homo sapiens (human)
neuropeptide signaling pathwayGlycine receptor subunit alpha-1Homo sapiens (human)
acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
visual perceptionGlycine receptor subunit alpha-1Homo sapiens (human)
adult walking behaviorGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal action potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neuromuscular process controlling postureGlycine receptor subunit alpha-1Homo sapiens (human)
negative regulation of transmission of nerve impulseGlycine receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, glycinergicGlycine receptor subunit alpha-1Homo sapiens (human)
righting reflexGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory postsynaptic potentialGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to amino acid stimulusGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to zinc ionGlycine receptor subunit alpha-1Homo sapiens (human)
cellular response to ethanolGlycine receptor subunit alpha-1Homo sapiens (human)
response to alcoholGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGlycine receptor subunit alpha-1Homo sapiens (human)
positive regulation of acrosome reactionGlycine receptor subunit alpha-1Homo sapiens (human)
chemical synaptic transmissionGlycine receptor subunit alpha-1Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neuropeptide signaling pathwayGlycine receptor subunit alpha-2Homo sapiens (human)
monoatomic ion transmembrane transportGlycine receptor subunit alpha-2Homo sapiens (human)
excitatory postsynaptic potentialGlycine receptor subunit alpha-2Homo sapiens (human)
cellular response to amino acid stimulusGlycine receptor subunit alpha-2Homo sapiens (human)
cellular response to zinc ionGlycine receptor subunit alpha-2Homo sapiens (human)
cellular response to ethanolGlycine receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGlycine receptor subunit alpha-2Homo sapiens (human)
regulation of membrane potentialGlycine receptor subunit alpha-2Homo sapiens (human)
chemical synaptic transmissionGlycine receptor subunit alpha-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
transmembrane signaling receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
protein bindingGlycine receptor subunit alpha-1Homo sapiens (human)
zinc ion bindingGlycine receptor subunit alpha-1Homo sapiens (human)
glycine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
extracellularly glycine-gated chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
taurine bindingGlycine receptor subunit alpha-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlycine receptor subunit alpha-1Homo sapiens (human)
neurotransmitter receptor activityGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityGlycine receptor subunit alpha-1Homo sapiens (human)
transmembrane signaling receptor activityGlycine receptor subunit alpha-2Homo sapiens (human)
glycine bindingGlycine receptor subunit alpha-2Homo sapiens (human)
extracellularly glycine-gated chloride channel activityGlycine receptor subunit alpha-2Homo sapiens (human)
glycine-gated chloride ion channel activityGlycine receptor subunit alpha-2Homo sapiens (human)
metal ion bindingGlycine receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlycine receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGlycine receptor subunit alpha-2Homo sapiens (human)
neurotransmitter receptor activityGlycine receptor subunit alpha-2Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityGlycine receptor subunit alpha-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
external side of plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
membraneGlycine receptor subunit alpha-1Homo sapiens (human)
dendriteGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
neuronal cell bodyGlycine receptor subunit alpha-1Homo sapiens (human)
perikaryonGlycine receptor subunit alpha-1Homo sapiens (human)
intracellular membrane-bounded organelleGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
postsynaptic membraneGlycine receptor subunit alpha-1Homo sapiens (human)
inhibitory synapseGlycine receptor subunit alpha-1Homo sapiens (human)
glycinergic synapseGlycine receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGlycine receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGlycine receptor subunit alpha-1Homo sapiens (human)
synapseGlycine receptor subunit alpha-1Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-1Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-1Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-2Homo sapiens (human)
intracellular membrane-bounded organelleGlycine receptor subunit alpha-2Homo sapiens (human)
postsynaptic membraneGlycine receptor subunit alpha-2Homo sapiens (human)
glycinergic synapseGlycine receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGlycine receptor subunit alpha-2Homo sapiens (human)
plasma membraneGlycine receptor subunit alpha-2Homo sapiens (human)
synapseGlycine receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGlycine receptor subunit alpha-2Homo sapiens (human)
neuron projectionGlycine receptor subunit alpha-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (72)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID356522Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 1 mg/kg, po for 5 days measured 24 hrs after final drug administration assessed per 5 mins by tilting type ambulometer test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID1082436Inhibition of fruit-infesting behavior of Cydia pomonella (codling moth) neonates infested in apple fruit plugs assessed as feeding deterrence index at 1 mg/mL2011Journal of agricultural and food chemistry, Oct-26, Volume: 59, Issue:20
Effects of Ginkgo biloba constituents on fruit-infesting behavior of codling moth (Cydia pomonella) in apples.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID356514Anxiolytic-like activity in ddY mouse assessed as time spent in open-sided arms at 1 mg/kg, po for 2 days measured 24 hrs after final drug administration by elevated plus-maze test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID356543Toxicity in ddY mouse assessed as induction of muscle relaxation at 1 mg/kg, po after 1 to 3 hrs2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID1082435Inhibition of fruit-infesting behavior of Cydia pomonella (codling moth) neonates infested in apple fruit plugs assessed as feeding deterrence index at 0.1 mg/mL2011Journal of agricultural and food chemistry, Oct-26, Volume: 59, Issue:20
Effects of Ginkgo biloba constituents on fruit-infesting behavior of codling moth (Cydia pomonella) in apples.
AID356513Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 2 mg/kg, po for 7 days measured 24 hrs after final drug administration assessed per 5 mins by tilting type ambulometer test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356511Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 2 mg/kg, po for 1 day measured after 1 hr assessed per 5 mins by tilting type ambulometer test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356505Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 1 mg/kg, po for 7 days measured 24 hrs after final drug administration assessed per 5 mins by tilting type ambulometer test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID281248Activity at human alpha-1-beta-GlyR expressed in HEK293 cells by FMP assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the pharmacophore of ginkgolides as glycine receptor antagonists.
AID356526Anxiolytic-like activity in ddY mouse assessed as pentobarbital-induced sleep time at 2 mg/kg, po administered 30 mins before pentobarbital challenge2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID356527Anxiolytic-like activity in ddY mouse assessed as pentobarbital-induced sleep time at 5 mg/kg, po administered 30 mins before pentobarbital challenge2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356504Anxiolytic-like activity in ddY mouse assessed as time spent in open-sided arms at 1 mg/kg, po for 7 days measured 24 hrs after final drug administration by elevated plus-maze test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID356533Anxiolytic-like activity in ddY mouse assessed as number of shuttle per hour at 5 mg/kg, po administered 30 mins before test by discrete shuttle avoidance test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356525Anxiolytic-like activity in ddY mouse assessed as pentobarbital-induced sleep time at 1 mg/kg, po administered 30 mins before pentobarbital challenge2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356512Anxiolytic-like activity in ddY mouse assessed as time spent in open-sided arms at 2 mg/kg, po for 7 days measured 24 hrs after final drug administration by elevated plus-maze test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID1707196Inhibition of [3H]PAF-acether binding to PAFR in rabbit platelet plasma membranes incubated for 1 hr2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID281249Activity at human alpha-2GlyR expressed in HEK293 cells by FMP assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the pharmacophore of ginkgolides as glycine receptor antagonists.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID356544Toxicity in ddY mouse assessed as body weight gain after repeated administration2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356534Anxiolytic-like activity in ddY mouse assessed as number of shocks per hour at 5 mg/kg, po administered 30 mins before test by discrete shuttle avoidance test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID356521Anxiolytic-like activity in ddY mouse assessed as time spent in open-sided arms at 1 mg/kg, po for 5 days measured 24 hrs after final drug administration by elevated plus-maze test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356532Anxiolytic-like activity in ddY mouse assessed as number of shocks per hour at 1 mg/kg, po administered 30 mins before test by discrete shuttle avoidance test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356516Anxiolytic-like activity in ddY mouse assessed as time spent in open-sided arms at 1 mg/kg, po for 3 days measured 24 hrs after final drug administration by elevated plus-maze test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1707177Inhibition of PAFR in New Zealand rabbit platelets assessed as reduction in PAF-induced platelet aggregation measured within 5 mins by aggregometry analysis2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID356520Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 1 mg/kg, po for 4 days measured 24 hrs after final drug administration assessed per 5 mins by tilting type ambulometer test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356515Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 1 mg/kg, po for 2 days measured 24 hrs after final drug administration assessed per 5 mins by tilting type ambulometer test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356523Toxicity in ddY mouse at 1 to 2 mg/kg, po2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356542Toxicity in ddY mouse assessed as induction of ataxia at 1 mg/kg, po after 1 to 3 hrs2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID281250Activity at human alpha-1GlyR expressed in HEK293 cells assessed as inhibition of 300 uM glycine-induced current by whole-cell patch clamp experiment2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the pharmacophore of ginkgolides as glycine receptor antagonists.
AID281247Activity at human alpha-1GlyR expressed in HEK293 cells by FMP assay2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
Probing the pharmacophore of ginkgolides as glycine receptor antagonists.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID356519Anxiolytic-like activity in ddY mouse assessed as time spent in open-sided arms at 1 mg/kg, po for 4 days measured 24 hrs after final drug administration by elevated plus-maze test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356539Half life in rat2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID356524Anxiolytic-like activity in ddY mouse assessed as pentobarbital-induced sleep time at 0.5 mg/kg, po administered 30 mins before pentobarbital challenge2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID356517Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 1 mg/kg, po for 3 days measured 24 hrs after final drug administration assessed per 5 mins by tilting type ambulometer test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356510Anxiolytic-like activity in ddY mouse assessed as time spent in open-sided arms at 2 mg/kg, po for 1 day measured after 1 hr by elevated plus-maze test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356528Anxiolytic-like activity in ddY mouse assessed as pentobarbital-induced sleep time at 10 mg/kg, po administered 30 mins before pentobarbital challenge2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID1082437Inhibition of fruit-infesting behavior of Cydia pomonella (codling moth) neonates infested in apple fruit plugs assessed as feeding deterrence index at 10 mg/mL2011Journal of agricultural and food chemistry, Oct-26, Volume: 59, Issue:20
Effects of Ginkgo biloba constituents on fruit-infesting behavior of codling moth (Cydia pomonella) in apples.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID356531Anxiolytic-like activity in ddY mouse assessed as number of shuttle per hour at 1 mg/kg, po administered 30 mins before test by discrete shuttle avoidance test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID356529Anxiolytic-like activity in ddY mouse assessed as pentobarbital-induced sleep time at 20 mg/kg, po administered 30 mins before pentobarbital challenge2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356508Anxiolytic-like activity in ddY mouse assessed as time spent in open-sided arms at 1 mg/kg, po for 1 day measured after 1 hr by elevated plus-maze test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356509Anxiolytic-like activity in ddY mouse assessed as ambulatory activity at 1 mg/kg, po for 1 day measured after 1 hr assessed per 5 mins by tilting type ambulometer test2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID356541Toxicity in ddY mouse assessed as induction of excitation at 20 mg/kg, po after 1 to 3 hrs2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID356540Toxicity in ddY mouse assessed as induction of sedation at 20 mg/kg, po after 1 to 3 hrs2003Journal of natural products, Oct, Volume: 66, Issue:10
An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (28.57)29.6817
2010's8 (57.14)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.70 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]